Abbott to launch pain management app

ABBOTT PARK - Abbott Thursday announced the upcoming launch of NeuroSphere myPath, a digital health app designed to track patient-perceived pain relief and general well-being associated with spinal cord stimulation or dorsal root ganglion therapy.

"The COVID-19 pandemic put a spotlight on the need for digital and remote health tools," said Keith Boettiger, vice president, Neuromodulation, Abbott. "The launch of the NeuroSphere myPath is one more example of how Abbott has been leading the way in providing remote ways to connect doctors and patients."

During the device trial period required before a permanent implant, the app allows patients to record their outcomes on pain and well-being while trialing their neurostimulation therapy.

The app is a digital innovation that will provide relief to the millions of Americans currently living with chronic pain that are eligible for spinal cord stimulation or DRG therapy, the company said.